By enhancing our understanding of this receptor, we are opening new doors to innovative treatments that go beyond symptom management to address the root causes of these conditions.
The Sigma-1 receptor (SIGMAR1) is a unique protein that plays a vital role in keeping the brain’s neurons healthy and functional. Located within the cell’s endoplasmic reticulum, SIGMAR1 acts like an air traffic controller, ensuring smooth communication between neurons and maintaining balance, especially during times of stress.
When activated, SIGMAR1 regulates essential cellular processes such as calcium signaling, energy production, and stress responses. Much like a skilled conductor harmonizing an orchestra, it restores order to the brain’s complex network, reducing oxidative stress, promoting resilience, and protecting neurons from damage caused by aging, disease, or injury. These actions are crucial for maintaining neuronal health and preventing degeneration.
Anavex’s proprietary SIGMACEPTOR™ Discovery Platform focuses on developing therapeutic candidates that activate SIGMAR1, such as ANAVEX®2-73 (blarcamesine). By modulating this receptor, our therapies aim to repair disrupted cellular communication and restore neuronal homeostasis. This approach targets the biological mechanisms that contribute to neurodegenerative conditions, aiming to provide new therapeutic possibilities for patients.
Our dedication to understanding and leveraging the Sigma-1 receptor (SIGMAR1) is paving the way for groundbreaking advancements in the treatment of neurodegenerative and rare diseases. By focusing on the mechanisms that drive these conditions, we are opening new possibilities for therapies that address their root causes and improve the lives of patients worldwide.
